BUY Infosys — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Intraday)10 Aug 2026, 10:09 am ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
7 advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·10 Aug · today
Sensex, Nifty open higher; HCL Tech, Tech Mahindra, Infosys, RIL shares lead gains
NewsGoogle News·6 Aug · 4d ago
Infosys Expands Metsä Group AI Partnership; Shares Rise 0.56%
NewsGoogle News·5 Aug · 4d ago
Infosys Finacle deploys wealth management platform at HDFC Bank, replacing legacy systems
NewsGoogle News·4 Aug · 6d ago
Infosys shares rise 2.06%, trading at Rs 1,153.40
NewsGoogle News·3 Aug · 1w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Infosys
- BUY — Vikas Sethi, Sethi Finmart23 Oct 2026 · Same day · target ₹1,175 · Expired
- BUY — Rakesh Bansal22 Oct 2026 · ~2 weeks · target ₹1,200 · SL hit
- BUY — Rakesh Bansal21 Oct 2026 · ~2 weeks · target ₹1,222 · Active
- BUY — Prakash Gaba14 Oct 2026 · ~2 weeks · target ₹1,100 · Target hit
- SELL — Kunal Bothra13 Oct 2026 · ~2 weeks · target ₹1,000 · Active
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

